Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Current Deferred Revenue (2022 - 2025)

Taysha Gene Therapies' Current Deferred Revenue history spans 4 years, with the latest figure at $5.5 million for Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 53.5% year-over-year to $5.5 million; the TTM value through Sep 2025 reached $5.5 million, down 53.5%, while the annual FY2024 figure was $9.8 million, 45.87% down from the prior year.
  • Current Deferred Revenue for Q3 2025 was $5.5 million at Taysha Gene Therapies, roughly flat from $5.5 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $33.6 million in Q4 2022 and bottomed at $5.5 million in Q2 2025.
  • The 4-year median for Current Deferred Revenue is $14.1 million (2024), against an average of $15.7 million.
  • The largest annual shift saw Current Deferred Revenue crashed 32.82% in 2024 before it plummeted 59.67% in 2025.
  • A 4-year view of Current Deferred Revenue shows it stood at $33.6 million in 2022, then crashed by 46.04% to $18.1 million in 2023, then crashed by 45.87% to $9.8 million in 2024, then crashed by 44.03% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Current Deferred Revenue are $5.5 million (Q3 2025), $5.5 million (Q2 2025), and $7.5 million (Q1 2025).